703092 |
Citrulline-nitric oxide cycle |
8.83E − 02 |
2.53E − 01 |
8.24E − 01 |
1.00E + 00 |
1 |
NOS2 |
142419 |
Phospholipases |
9.82E − 02 |
2.53E − 01 |
8.24E − 01 |
1.00E + 00 |
1 |
PLA2G2E, PLA2G2A |
545273 |
Glycoaminoglycan-protein linkage region biosynthesis |
1.05E − 01 |
2.53E − 01 |
8.24E − 01 |
1.00E + 00 |
1 |
B3GAT1 |
545323 |
Urate biosynthesis/inosine 5′-phosphate degradation |
1.05E − 01 |
2.53E − 01 |
8.24E − 01 |
1.00E + 00 |
1 |
NT5E |
142383 |
Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde |
1.21E − 01 |
2.53E − 01 |
8.24E − 01 |
1.00E + 00 |
1 |
IDO1 |
KEGG |
|
|
|
|
|
|
|
83051 |
Cytokine-cytokine receptor interaction |
3.05E − 61 |
5.54E − 59 |
3.21E − 58 |
5.54E − 59 |
69 |
IL10, IL10RA, IL12A, IL12B, IL13, IL13RA1, TNFRSF9, IL17A, PDGFB, TNFSF12, IL17B, TNFRSF14, TNFRSF10C, CCL26,IL17F, TNFRSF4, IL22RA2, IL21, CCL7, CCR6, CCL11, CCL13, CCR8, CCL15, CCL16, CCL18, CCL19, CCL20, CCL22, CCL24, CXCL11, XCL1, KIT, CX3CL1, CXCL12, IL19, CCR10, XCR1, CXCL13, PPBP, IL23A, IFNA2, IFNAR1, IFNB1, IFNG, TGFBR1, LIF, CSF1R, CSF2, CSF2RB, CSF3R, IL20, IL22,, CD40, TNFRSF13C, LTA, IL1RAP, IL2, IL3, IL4, IL4R, IL5, IL6, IL6R, IL7, IL26, CXCR1, IL9, CXCR2 |
83078 |
Hematopoietic cell lineage |
4.22E − 35 |
3.84E − 33 |
2.22E − 32 |
7.67E − 33 |
34 |
HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, CD55, MME, KIT, CR2, TFRC, CD1A, CD3E, CSF1R, CSF2, CD8A, CD9, CSF3R, CD19, MS4A1, CD22, CD34, CD44, CD59, IL3, IL4, IL4R, IL5, IL6, IL6R, IL7 |
842771 |
Inflammatory bowel disease (IBD) |
4.58E − 32 |
2.78E − 30 |
1.61E − 29 |
8.34E − 30 |
28 |
IL10, IL12A, IL12B, IL13, IL17A, HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, GATA3, IL17F, STAT6, IL21, RELA, IL23A, IFNG, IL22, RORC, IL2, IL4, IL4R, IL5, IL6 |
83077 |
Jak-STAT signaling pathway |
4.56E − 26 |
1.19E − 24 |
6.86E − 24 |
8.30E − 24 |
33 |
IL10, IL10RA, IL12A, IL12B, IL13, IL13RA1, BCL2, STAT5A, STAT6, PTPN6, IL22RA2, IL21, IL19, IL23A, IFNA2, IFNAR1, IFNB1, IFNG, LIF, CSF2, CSF2RB, CSF3R, IL20, IL22, IL2, IL3, IL4, IL4R, IL5, IL6, IL6R, IL7, IL9 |
213780 |
Tuberculosis |
3.41E − 25 |
6.89E − 24 |
3.99E − 23 |
6.20E − 23 |
34 |
IL10, IL10RA, IL12A, IL12B, CEBPB, HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, BCL2, CD209, BID, FCGR2A, FCGR2B, CARD9, NOS2, CASP3, RELA, TLR9, IL23A, IFNA2, IFNB1, IFNG, TIRAP, IRAK4, CD74, MAPK11, CTSS, IL6 |
83120 |
Asthma |
4.56E − 24 |
8.30E − 23 |
4.80E − 22 |
8.30E − 22 |
18 |
IL10, IL13, HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, FCER1A, CCL11, CD40, IL3, IL4, IL5, IL9 |
125138 |
Viral myocarditis |
2.26E − 16 |
2.06E − 15 |
1.19E − 14 |
4.12E − 14 |
17 |
HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, CD55, BID, CASP3, CD80, CD86, CD40 |
373901 |
HTLV-I infection |
2.85E − 15 |
2.35E − 14 |
1.36E − 13 |
5.18E − 13 |
29 |
HLA-B, PDGFB, HLA-C, HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, ETS1, STAT5A, VCAM1, RELA, RELB, LCK, SLC2A1, TGFBR1, CD3E, CSF2, EGR1, EGR2, CD40, TNFRSF13C, LTA, IL2, IL6 |
213306 |
Measles |
4.04E − 12 |
2.53E − 11 |
1.47E − 10 |
7.35E − 10 |
19 |
IL12A, IL12B, IL13, CD46, TNFRSF10C, CD209, STAT5A, FCGR2B, RELA, TLR9, IFNA2, IFNAR1, IFNB1, IFNG, CD3E, IRAK4, IL2, IL4, IL6 |
83074 |
Antigen processing and presentation |
7.12E − 12 |
4.32E − 11 |
2.50E − 10 |
1.30E − 09 |
15 |
HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, IFNG, CD8A, CD74, CTSS |
217173 |
Influenza A |
4.98E − 11 |
2.75E − 10 |
1.59E − 09 |
9.07E − 09 |
20 |
IL12A, IL12B, HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1,HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, TNFRSF10C, RELA, IFNA2, IFNAR1, IFNB1, IFNG, IRAK4, MAPK11, IL6 |
Pathway interaction database |
|
|
|
|
|
|
|
137933 |
IL4-mediated signaling events |
7.74E − 16 |
8.36E − 14 |
4.40E − 13 |
8.36E − 14 |
17 |
IL10, IL13RA1, CEBPB, AICDA, ETS1, CCL26, STAT5A, STAT6, PTPN6, PIGR, CCL11, THY1, EGR2, LTA, IL4, IL4R, IL5 |
137922 |
IL12-mediated signaling events |
9.23E − 15 |
4.99E − 13 |
2.62E − 12 |
9.97E − 13 |
16 |
IL12A, IL12B, HLA-DRA, HLA-DRB1, STAT5A, STAT6, EOMES, NOS2, RELA, RELB, LCK, IFNG, CD3E, CD8A, IL2, IL4 |
138000 |
IL23-mediated signaling events |
1.32E − 12 |
4.75E − 11 |
2.50E − 10 |
1.42E − 10 |
12 |
IL12B, IL17A, IL17F, STAT5A, NOS2, IL19, RELA, IL23A, IFNG, CD3E, IL2, IL6 |
137929 |
IL27-mediated signaling events |
1.43E − 11 |
3.87E − 10 |
2.04E − 09 |
1.55E − 09 |
10 |
IL12A, IL12B, IL17A, GATA3, STAT5A, IFNG, EBI3, IL2, IL6, IL27 |
138058 |
BCR signaling pathway |
3.00E − 07 |
4.05E − 06 |
2.13E − 05 |
3.24E − 05 |
10 |
ETS1, PTPN6, FCGR2B, BTK, POU2F2, RELA, CD19, CD22, CD79A, CD79B |
138055 |
TCR signaling in naive CD8 + T cells |
2.28E − 04 |
1.30E − 03 |
6.82E − 03 |
2.46E − 02 |
6 |
PTPN6, LCK, CD3E, CD8A, CD80, CD86 |
137939 |
Direct p53 effectors |
2.95E − 03 |
1.33E − 02 |
7.00E − 02 |
3.18E − 01 |
8 |
SPP1, BCL2, TNFRSF10C, BID, CD82, MAP4K4, CX3CL1, LIF |
138081 |
FAS (CD95) signaling pathway |
3.67E − 03 |
1.42E − 02 |
7.46E − 02 |
3.97E − 01 |
4 |
BID, BTK, CASP3, MAPK11 |
137995 |
HIV-1 Nef: Negative effector of Fas and TNF-alpha |
3.67E − 03 |
1.42E − 02 |
7.46E − 02 |
3.97E − 01 |
4 |
BCL2, BID, CASP3, RELA |
137944 |
IL1-mediated signaling events |
2.58E − 02 |
6.45E − 02 |
3.40E − 01 |
1.00E + 00 |
3 |
TOLLIP, RELA, IRAK4 |
REACTOME
|
|
|
|
|
|
|
|
1269310 |
Cytokine Signaling in Immune system |
3.81E − 46 |
2.02E − 43 |
1.39E − 42 |
2.02E − 43 |
86 |
IL10, IL10RA, IL12A, IL12B, IL13, IL13RA1, IL16, TRAF3, TNFRSF9, IL17A, HLA-B, PDGFB, HLA-C, TNFSF12, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, TNFRSF14, GATA3, PSMB10, BCL2, PTAFR, IL1RL2, IL17F, PTK2, STAT5A, STAT6, TNFRSF4, PTPN6, IL22RA2, TOLLIP, CCL11, CCL19, CCL20, CCL22, KIT, NOS2, VCAM1, IL19, RAG1, RAG2, ZEB1, FN1, DUSP4, IRF8, CASP3, RELA, RELB, LCK, IL23A, S1PR1, IFNA2, IFNAR1, IFNB1, IFNG, LIF, CSF1R, CSF2, CSF2RB, CSF3R, EBI3, EGR1, IL20, CD80, CD86, IL22, CD40, IRAK4, CD44, TNFRSF13C, LTA, RORC, IL1RAP, IL2, IL3, IL4, IL4R, IL5, IL6, IL6R, IL7, IL27, IL9 |
1269318 |
Signaling by Interleukins |
2.98E − 33 |
7.91E − 31 |
5.42E − 30 |
1.58E − 30 |
62 |
IL10, IL10RA, IL12A, IL12B, IL13, IL13RA1, IL16, IL17A, PDGFB, GATA3, PSMB10, BCL2, PTAFR, IL1RL2, IL17F, PTK2, STAT5A, STAT6, PTPN6, IL22RA2, TOLLIP, CCL11, CCL19, CCL20, CCL22, KIT,NOS2, VCAM1, IL19, RAG1, RAG2, ZEB1, FN1, DUSP4, CASP3, RELA, LCK, IL23A, S1PR1, LIF, CSF1R, CSF2, CSF2RB, CSF3R, EBI3, IL20, CD80, CD86, IL22, IRAK4, RORC, IL1RAP, IL2, IL3, IL4, IL4R, IL5, IL6, IL6R,IL7, IL27, IL9 |
1269203 |
Innate Immune System |
4.93E − 25 |
8.72E − 23 |
5.98E − 22 |
2.62E − 22 |
82 |
MASP1, TRAF3, HLA-B, PDGFB, HLA-C, MAPKAPK2, CTSC, PECAM1, MBL2, PSMB10, CD55, CD46, BCL2, DEFB103B, PTAFR, CD209, PTK2, STAT6, DEFB1, DEFB4A, CFD, PTPN6, FCAR, FCER1A, PIGR, FCGR2A, CARD9, BTK, MIF, PLA2G2A, TOLLIP, C1R, C1S, C4A, PLAU, C4BPA, CCR6, MME, C6, C7, C8A, C8B, C9, KIT, NOS2, GPI, LILRA3, VTN, CLEC6A, FN1, ATG7, ITLN1, DUSP4, ICAM2, ICAM3, RELA, RELB, TLR9, LCK, PPBP, CFI, IFNA2, LGALS3, IFNB1, CSF2, CSF2RB, CD19, SIGIRR, CD80, CD86, TIRAP, IRAK4, CD44, CD59, MAPK11, IL2, IL3, IL5, CTSS, CXCR1, MASP2, CXCR2 |
1269171 |
Adaptive Immune System |
1.51E − 15 |
1.15E − 13 |
7.86E − 13 |
8.03E − 13 |
52 |
HLA-B, PDGFB, HLA-C, HLA-DMA, HLA-DMB, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, CTSC, HLA-DRB1, TNFRSF14, PSMB10, PTPN22, CD209, PTPN6, SLAMF6, FCGR2B, BTK, KIT, KLRB1, LILRB5, VCAM1, ICOSLG, LILRA1, LILRA3, LILRA2, ATG7, ICAM2, ICAM3, ICAM4, RELA, BTLA, LCK, CD1A, CD3E, CD8A, CD19, CD22, CD80, CD86, ICAM5, TIRAP, CD34, CD40, CD74, CD79A, CD79B, CTLA4, CTSS |
1269201 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
5.01E − 14 |
2.66E − 12 |
1.82E − 11 |
2.66E − 11 |
21 |
HLA-B, HLA-C, SLAMF6, FCGR2B, KLRB1, LILRB5, VCAM1, LILRA1, LILRA3, LILRA2, ICAM2, ICAM3, ICAM4, CD1A, CD3E, CD8A, CD19, CD22, ICAM5, CD34, CD40 |
1269546 |
Peptide ligand-binding receptors |
6.17E − 08 |
1.82E − 06 |
1.25E − 05 |
3.27E − 05 |
17 |
CCR6, CCL13, CCR8, CCL16, CCL19, CCL20, CXCL11, XCL1, CX3CL1, CXCL12, CCR10, XCR1, CXCL13, PPBP, EDNRB, CXCR1, CXCR2 |
1269545 |
Class A/1 (Rhodopsin-like receptors) |
4.71E − 07 |
1.14E − 05 |
7.79E − 05 |
2.50E − 04 |
21 |
PTAFR, PTGER4, CCR6, CCL13,CCR8,CCL16, CCL19, CCL20, CXCL11, XCL1, CX3CL1, CXCL12, CCR10, XCR1, CXCL13, GPR183, PPBP, S1PR1, EDNRB, CXCR1, CXCR2 |
1269340 |
Hemostasis |
1.15E − 04 |
1.47E − 03 |
1.01E − 02 |
6.09E − 02 |
26 |
CD244, PDGFB, PECAM1, GATA3, PTK2, CFD, PTPN6, MIF, PLAU, NOS2, SELE, SELPLG, FN1, LCK, PPBP, IFNA2, IFNB1, CSF2, CSF2RB, CD9, CD44, CD48, CD74, IL2, IL3, IL5 |
1269501 |
MAPK family signaling cascades |
3.27E − 04 |
3.40E − 03 |
2.33E − 02 |
1.74E − 01 |
15 |
PDGFB, PSMB10, PTK2, KIT, RAG1, RAG2, FN1, DUSP4, CSF2, CSF2RB, IL2, IL3, IL5, IL6, IL6R |
1269240 |
Toll Like Receptor TLR6:TLR2 Cascade |
3.46E − 04 |
3.40E − 03 |
2.33E − 02 |
1.84E − 01 |
8 |
MAPKAPK2, BTK, DUSP4, RELA, SIGIRR, TIRAP, IRAK4, MAPK11 |
Gen MAPP
|
|
|
|
|
|
|
|
MAP00400 |
Phenylalanine tyrosine and tryptophan biosynthesis |
1.38E − 01 |
5.02E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
BID |
MAP_kinase_activity |
MAP kinase activity |
1.38E − 01 |
5.02E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
MAPK11 |
MAP00010 |
Glycolysis Gluconeogenesis |
2.47E − 01 |
5.02E − 01 |
1.00E + 00 |
1.00E + 00 |
2 |
BID, GPI |
MAP00030 |
Pentose phosphate |
2.70E − 01 |
5.02E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
GPI |
MAP00590 |
Prostaglandin and leukotriene metabolism |
2.96E − 01 |
5.02E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
PLA2G2A |
MAP00500 |
Starch and sucrose metabolism |
3.34E − 01 |
5.02E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
GPI |
MAP00330 |
Arginine and proline metabolism |
5.05E − 01 |
5.81E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
NOS2 |
MAP00380 |
Tryptophan metabolism |
5.73E − 01 |
5.81E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
IDO1 |
MAP00561 |
Glycerolipid metabolism |
5.81E − 01 |
5.81E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
PLA2G2A |
MSigDB C2 BIOCARTA (v6.0) |
|
|
|
|
|
|
|
M5883 |
Genes encoding secreted soluble factors |
4.86E − 27 |
7.82E − 25 |
4.43E − 24 |
7.82E − 25 |
46 |
IL10, IL12A, IL12B, IL13, IL16, IL17A, PDGFB, TNFSF12, IL17B, CCL26, IL17F, CCL7, CCL11, CCL13, CCL15, CCL16, CCL18, CCL19, CCL20, CCL22, CCL24, CXCL11, XCL1, CX3CL1, CXCL12, IL19, CXCL13, PPBP, IL23A, IFNA2, IFNB1, IFNG, LIF, CSF2, EBI3, IL20, IL22, LTA, IL2, IL3, IL4, IL5, IL6, IL7, IL26, IL9 |
M17406 |
Cytokine Network |
2.71E − 22 |
2.18E − 20 |
1.24E − 19 |
4.36E − 20 |
15 |
IL10, IL12A, IL12B, IL13, IL16, IL17A, IFNB1, IFNG, LTA, IL2, IL3, IL4, IL5, IL6, IL9 |
M6910 |
Cytokines and Inflammatory Response |
5.19E − 21 |
2.78E − 19 |
1.58E − 18 |
8.35E − 19 |
16 |
IL10, IL12A, IL12B, IL13, HLA-DRA, HLA-DRB1, IFNB1, IFNG, CSF2, LTA, IL2, IL3, IL4, IL5, IL6, IL7 |
M5885 |
Ensemble of genes encoding ECM-associated proteins including ECM-affilaited proteins, ECM regulators and secreted factors |
7.80E − 21 |
3.14E − 19 |
1.78E − 18 |
1.26E − 18 |
57 |
IL10, IL12A, IL12B, IL13, MASP1, IL16, IL17A, PDGFB, TNFSF12, CTSC, IL17B, MBL2, CCL26, IL17F, CD209, PLAU, CCL7, CCL11, CCL13, CCL15, CCL16, CCL18, CCL19, CCL20, CCL22, CCL24, CXCL11, XCL1, CX3CL1, CXCL12, IL19, CLEC6A, ITLN1, CXCL13, ITLN2, PPBP, IL23A, IFNA2, LGALS3, IFNB1, IFNG, LIF, CSF2, EBI3, IL20, IL22, LTA, IL2, IL3, IL4, IL5, CTSS, IL6, IL7, IL26, IL9, MASP2 |
M5889 |
Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins |
4.62E − 17 |
1.49E − 15 |
8.43E − 15 |
7.44E − 15 |
61 |
IL10, IL12A, IL12B, IL13, MASP1, IL16, IL17A, PDGFB, TNFSF12, SPP1, CTSC,IL17B, MBL2, CCL26, IL17F, CD209, PLAU, CCL7,CCL11, CCL13, CCL15,CCL16, CCL18, CCL19, CCL20,CCL22, CCL24, CXCL11,XCL1, CX3CL1, CXCL12, IL19, VTN,CLEC6A, FN1, ITLN1, CXCL13,ITLN2, PPBP, IL23A,IFNA2, LGALS3, IFNB1, IFNG, TGFBI, LIF, CSF2, EBI3, IL20, IL22, LTA, IL2, IL3, IL4, IL5, CTSS, IL6, IL7, IL26, IL9, MASP2 |
M1467 |
The Co-Stimulatory Signal During T-cell Activation |
4.81E − 11 |
7.03E − 10 |
3.98E − 09 |
7.74E − 09 |
9 |
HLA-DRA, HLA-DRB1, ICOSLG, LCK, CD3E, CD80, CD86, CTLA4, IL2 |
M3952 |
Cells and Molecules involved in local acute inflammatory response |
1.02E − 05 |
7.46E − 05 |
4.22E − 04 |
1.64E − 03 |
5 |
C6, C7, VCAM1, SELPLG,IL6 |
M18215 |
Role of Tob in T-cell activation |
3.16E − 05 |
2.21E − 04 |
1.25E − 03 |
5.08E − 03 |
5 |
IFNG, TGFBR1, CD3E, IL2, IL4 |
M13968 |
HIV-I Nef: negative effector of Fas and TNF |
6.46E − 04 |
3.15E − 03 |
1.78E − 02 |
1.04E − 01 |
6 |
BCL2,PTK2, BID, CASP3, RELA, ARHGDIB |
M13247 |
T Cytotoxic Cell Surface Molecules |
1.90E − 03 |
6.80E − 03 |
3.85E − 02 |
3.06E − 01 |
3 |
CD3E, CD8A, THY1 |
Panther DB |
|
|
|
|
|
|
|
P00036 |
Interleukin signaling pathway |
6.51E − 19 |
2.47E − 17 |
1.05E − 16 |
2.47E − 17 |
22 |
IL10,IL10RA, IL12A,IL13, IL13RA1, IL17A, MAPKAPK2, IL17F, STAT5A, STAT6, IL21, IL23A, IL2, IL4, IL4R, IL5, IL6, IL6R, IL7, CXCR1, IL9, CXCR2 |
P00031 |
Inflammation mediated by chemokine and cytokine signaling pathway |
4.36E − 07 |
8.28E − 06 |
3.50E − 05 |
1.66E − 05 |
16 |
CCL26, CCL7, CCR6, CCL11, CCL13, CCR8, CCL18, CCL20, CCL22, CX3CL1, CCR10, XCR1, IFNAR1, IFNG, CXCR1, CXCR2 |
P00053 |
T cell activation |
7.23E − 05 |
8.13E − 04 |
3.44E − 03 |
2.75E − 03 |
8 |
HLA-DPA1, HLA-DQA1, HLA-DRA, LCK, CD3E, CD80, CD86, CD74 |
P00010 |
B cell activation |
8.56E − 05 |
8.13E − 04 |
3.44E − 03 |
3.25E − 03 |
7 |
PTPN6, BTK, CD19, CD22, CD79A, CD79B, MAPK11 |
P00054 |
Toll receptor signaling pathway |
2.14E − 03 |
1.62E − 02 |
6.86E − 02 |
8.12E − 02 |
5 |
TOLLIP, RELA, TLR9, IFNB1, IRAK4 |
P00006 |
Apoptosis signaling pathway |
2.67E − 03 |
1.69E − 02 |
7.14E − 02 |
1.01E − 01 |
7 |
BCL2, BID, BCL2L11, CASP3, RELA, RELB, LTA |
P00035 |
Interferon-gamma signalingpathway |
1.42E − 02 |
7.69E − 02 |
3.25E − 01 |
5.39E − 01 |
3 |
PTPN6, IFNG, MAPK11 |
P00046 |
Oxidative stress response |
5.17E − 02 |
1.86E − 01 |
7.88E − 01 |
1.00E + 00 |
3 |
BCL2, DUSP4, MAPK11 |
P00047 |
PDGF signaling pathway |
8.39E − 02 |
2.44E − 01 |
1.00E + 00 |
1.00E + 00 |
5 |
PDGFB, MAPKAPK2, ETS1, STAT5A, STAT6 |
P00034 |
Integrin signalling pathway |
5.94E − 01 |
7.28E − 01 |
1.00E + 00 |
1.00E + 00 |
3 |
ITGAE, PTK2, FN1 |
Pathway Ontology |
|
|
|
|
|
|
|
PW:0000104 |
intrinsic apoptotic |
1.82E − 03 |
7.63E − 02 |
3.30E − 01 |
7.63E − 02 |
4 |
BCL2, BID, BCL2L11, CASP3 |
PW:0000515 |
Interleukin-10 signaling |
7.84E − 01 |
1.57E − 01 |
6.78E − 01 |
6.78E − 01 |
1 |
IL10 |
PW:0000516 |
Interleukin-6 signaling |
7.84E − 01 |
1.57E − 01 |
6.78E − 01 |
6.78E − 01 |
1 |
IL6 |
PW:0000499 |
Nuclear Factor Kappa B signaling |
9.58E − 01 |
1.60E − 01 |
6.91E − 01 |
6.91E − 01 |
2 |
RELA, RELB |
PW:0000009 |
programmed cell death |
1.00E + 00 |
1.80E − 01 |
7.78E − 01 |
7.78E − 01 |
2 |
BCL2, CASP3 |
PW:0000102 |
The extracellular signal-regulated RAF/MEK/ERK signaling |
8.14E − 02 |
2.18E − 01 |
9.44E − 01 |
1.00E + 00 |
2 |
SPP1, S1PR1 |
PW:0000529 |
angiotensin (1-7) signaling |
8.83E − 02 |
2.18E − 01 |
9.44E − 01 |
1.00E + 00 |
1 |
MME |
PW:0000106 |
extrinsic apoptotic |
1.05E − 01 |
2.45E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
CASP3 |
PW:0000559 |
hexosamine biosynthetic |
1.21E − 01 |
2.55E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
GPI |
PW:0000228 |
G protein signaling via Galphai family |
1.53E − 01 |
2.80E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
S1PR1 |
SMPDB |
|
|
|
|
|
|
|
SMP00094 |
Sulindac Pathway |
1.21E − 01 |
4.52E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
PLA2G2A |
SMP00040 |
Glycolysis |
2.14E − 01 |
4.52E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
GPI |
SMP00063 |
Tryptophan Metabolism |
2.70E − 01 |
4.52E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
IDO1 |
SMP00379 |
NifedipinePathway |
2.83E − 01 |
4.52E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
EDNRB |
SMP00006 |
Tyrosine Metabolism |
3.59E − 01 |
4.84E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
MIF |
SMP00320 |
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine |
4.57E − 01 |
4.84E − 01 |
1.00E + 00 |
1.00E + 00 |
1 |
MAPK11 |